FGF23 can be reduced in anemic patients by i.v. iron therapy (Wolf et al., 2020), and by FC in rodent models of CKD (Francis et al., 2019); however, it is unknown which manifestations of CKD may be iron‐ or FGF23‐dependent. Here, FGF23 is linked to chronic kidney disease.